Charles River Labs Q3 2025 Financial Results and Updated Guidance

Details

reported its third-quarter 2025 financial results, showing a 0.5% decrease in total revenue to $1.00 billion. GAAP earnings per share were $1.10, down from $1.33 in the same period of 2024, primarily due to a loss from venture capital and strategic investments. On a non-GAAP basis, earnings per share were $2.43, a 6.2% decrease from $2.59 in 2024. The company also updated its 2025 financial guidance, narrowing its revenue outlook to the middle and upper ends of the previous range and raising its non-GAAP earnings per share outlook.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.